Few companies have experienced such a sudden reversal of fortune as the health care technology startup Theranos. The once-celebrated brainchild of Stanford University student Elizabeth Holmes is now the target of a criminal investigation.
We should be skeptical of claims made by businesses about new products or services. But we should also be skeptical about accusations made by former employees, potential competitors, and government regulators.
I still believe there is a bright future for Theranos’s vision of making blood tests more convenient, inexpensive, and proactive. Some of the charges against the firm seem petty. Unfortunately, it’s hard to ignore the government report that says Theranos’s finger stick system failed quality control tests at an alarming rate, and in some cases the QC failures were ignored.
Saturday, May 14. 2016
Theranos revisited
Comments
Display comments as
(Linear | Threaded)
Add Comment
